Author

John Pallante

Observed names: J Pallante, J. Pallante

Institution: HiFiBiO Therapeutics (United States)

Observed institutions: Novartis (Switzerland), HiFiBiO Therapeutics (United States), Novartis (United States)

OpenAlex ID: A5056757246

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study

2012 · Claus F Vogelmeier, Eric D Bateman, et al. · The Lancet Respiratory Medicine · 316

Once-Daily QVA149 Demonstrates Superior Outcomes in COPD Patients Previously Treated With Fixed-Dose Long-Acting β2-Agonist/Inhaled Corticosteroid (LABA/ICS): The ILLUMINATE Study

2014 · Karen Mezzi, John Pallante, et al. · CHEST Journal · 4

A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors.

2024 · Anthony B. El-Khoueiry, Elena Garralda, et al. · Journal of Clinical Oncology · 3

Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors.

2024 · Desamparados Roda, Jon Zugazagoitia, et al. · Journal of Clinical Oncology · 2

1233 Predictive and generative AI to guide the clinical development of HFB200301, a first-in-class TNFR2 agonist: drug intelligence science (DIS®)

2024 · Jack Pollard, Spencer Huggett, et al. · Regular and Young Investigator Award Abstracts

1011P Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors

2024 · D. Roda Perez, J. Zugazagoitia, et al. · Annals of Oncology

Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β 2 -agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study

2013 · Karen Mezzi, Danny McBryan, et al. · European Respiratory Journal

QVA149 einmal täglich verbessert signifikant die Lungenfunktion und die Symptome bei COPD Patienten im Vergleich zu Fluticason/Salmeterol zweimal täglich: die ILLUMINATE Studie

2013 · C Vogelmeier, E Bateman, et al. · Pneumologie

P194 Once-Daily QVA149 Provides Superior Bronchodilation and Improves Lung Function Versus Twice-Daily Fluticasone/Salmeterol in COPD Patients: The ILLUMINATE Study

2012 · C Vogelmeier, E Bateman, et al. · Thorax

Works count: 9

Citation count: 325

H-index: 3

I10-index: 1